Back to Search
Start Over
Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial.
- Source :
-
Neurology [Neurology] 2020 Nov 10; Vol. 95 (19), pp. e2658-e2665. Date of Electronic Publication: 2020 Sep 10. - Publication Year :
- 2020
-
Abstract
- Objective: To determine whether treatment with escitalopram compared with placebo would lower CSF β-amyloid 42 (Aβ <subscript>42</subscript> ) levels.<br />Rationale: Serotonin signaling suppresses Aβ <subscript>42</subscript> in animal models of Alzheimer disease (AD) and young healthy humans. In a prospective study in older adults, we examined dose and treatment duration effects of escitalopram.<br />Methods: Using lumbar punctures to sample CSF levels before and after a course of escitalopram treatment, cognitively normal older adults (n = 114) were assigned to placebo, 20 mg escitalopram × 2 weeks, 20 mg escitalopram × 8 weeks, or 30 mg escitalopram × 8 weeks; CSF sampled pretreatment and posttreatment and within-subject percent change in Aβ <subscript>42</subscript> was used as the primary outcome in subsequent analyses.<br />Results: An overall 9.4% greater reduction in CSF Aβ <subscript>42</subscript> was found in escitalopram-treated compared with placebo-treated groups ( p < 0.001, 95% confidence interval [CI] 4.9%-14.2%, d = 0.81). Positive baseline Aβ status (CSF Aβ <subscript>42</subscript> levels <250 pg/mL) was associated with smaller Aβ <subscript>42</subscript> reduction ( p = 0.006, 95% CI -16.7% to 0.5%, d = -0.52) compared with negative baseline amyloid status (CSF Aβ <subscript>42</subscript> levels >250 pg/mL).<br />Conclusions: Short-term longitudinal doses of escitalopram decreased CSF Aβ <subscript>42</subscript> in cognitively normal older adults, the target group for AD prevention.<br />Clinicaltrialsgov Identifier: NCT02161458.<br />Classification of Evidence: This study provides Class II evidence that for cognitively normal older adults, escitalopram decreases CSF Aβ <subscript>42</subscript> .<br /> (© 2020 American Academy of Neurology.)
- Subjects :
- Aged
Aged, 80 and over
Amyloid beta-Peptides drug effects
Citalopram pharmacology
Cohort Studies
Dose-Response Relationship, Drug
Female
Healthy Volunteers
Humans
Male
Middle Aged
Peptide Fragments drug effects
Prospective Studies
Selective Serotonin Reuptake Inhibitors pharmacology
Amyloid beta-Peptides cerebrospinal fluid
Citalopram administration & dosage
Duration of Therapy
Peptide Fragments cerebrospinal fluid
Selective Serotonin Reuptake Inhibitors administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1526-632X
- Volume :
- 95
- Issue :
- 19
- Database :
- MEDLINE
- Journal :
- Neurology
- Publication Type :
- Academic Journal
- Accession number :
- 32913021
- Full Text :
- https://doi.org/10.1212/WNL.0000000000010725